Genesis Therapeutics | LinkedIn (original) (raw)

Biotechnology Research

Burlingame, California 11,439 followers

Unifying AI and Biotech to accelerate the discovery of new medicines

Discover all 110 employees

About us

Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020). Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. We are rapidly growing our team with a variety of openings on our machine learning, computational chemistry, and software teams (primarily located in the Bay Area) and our chemistry, biology, and clinical teams (primarily located in San Diego). To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Burlingame, California

Type

Privately Held

Specialties

Deep Learning, Drug Discovery, Artificial Intelligence, and Drug Development

Locations

Employees at Genesis Therapeutics

Updates

We’re honored to share that we collaborated with the Massachusetts Institute of Technology team on the Boltz-1 model! This is the first fully accessible open-source release of a co-folding model for biomolecular structure prediction that achieves state-of-the-art accuracy. Read the paper here: https://lnkd.in/gGeh_MKn

PhD at MIT in Machine Learning | Generative Models for Structural Biology | BA at University of Cambridge | LeadTheFuture
23h Edited
Thrilled to announce Boltz-1, the first open-source and commercially available model to achieve AlphaFold3-level accuracy on biomolecular structure prediction! An exciting effort led with Jeremy Wohlwend and Saro Passaro with the help of an amazing team at MIT Jameel Clinic - AI & Health and in collaboration with Genesis Therapeutics! Check out: - Blog-post: https://lnkd.in/eDBfurAY- Technical report: https://lnkd.in/efFE2Ehe- Code, model, and instructions: https://lnkd.in/ezDA9pjiBy releasing training and inference code, model weights, and datasets under the MIT license, we aim to establish Boltz-1 as a modeling backbone for researchers worldwide, setting a new standard in open-source structural biology. A big shoutout to the whole Boltz-1 team: Jeremy Wohlwend, Saro Passaro, Mateo Reveiz, Ken Leidal, Wojtek Swiderski, Tally Portnoi, Itamar Chinn, Jacob Silterra, Tommi Jaakkola and Regina Barzilay!
Today, we announced an additional investment from NVentures, NVIDIA’s venture capital arm. We’re also collaborating with NVIDIA on key computational methods and AI architectures relevant to drug discovery, such as equivariant neural networks. We look forward to leveraging the NVIDIA team’s expertise as we continue building novel generative and predictive AI techniques to accelerate and optimize small molecule drug discovery. Learn more at https://lnkd.in/gqmwXjaK #AI #DrugDiscovery #GenAI #Biotech
Genesis Therapeutics reposted this

Founder and CEO at Genesis Therapeutics, Inc.
1mo
Reminder to join us at Stanford today for a talk on AI-driven drug discovery with Genesis’ GEMS platform and insights from Genesis' team! *Note the room change to Gates 415
Genesis Therapeutics reposted this

Founder and CEO at Genesis Therapeutics, Inc.
1mo Edited
🌟 Excited to announce our upcoming talk at Stanford University! (Open to everyone) 🌟 Title: GEMS: Generative Modeling for Small Molecule Drug Discovery at Genesis As a proud Stanford alumnus, I’m excited to return to the place where my journey began and share my story of founding Genesis Therapeutics. I’ll also be joined by our Director of ML, Maruan Al-Shedivat, PhD, who will speak about some of the challenges of applying AI to structure-based drug discovery and the evolution of our cutting-edge technology at Genesis. 🔍 What to Expect: *Insights into the critical challenges in developing the novel AI approaches required for small molecule drug discovery *An overview of Genesis’ AI platform, GEMS (Genesis Exploration of Molecular Space) *A deep dive into diffusion-based generative models and real-world performance 🗓️ Date & Time: October 8 (Tue) 2:30 - 3:30pm 📍 Location: Stanford University, Gates Building Room 403 *Note that this talk is open to the public, and all are welcome to join. Join us as we connect the dots between academia and industry, and share our vision for the future of drug discovery. I look forward to engaging with the Stanford community once again #DrugDiscovery #AI #GenesisTherapeutics #Biophysics #MachineLearning
11,439 followers
2mo Edited
We’re thrilled to announce our collaboration with Gilead! Together, we’re combining forces to accelerate groundbreaking discoveries and push the boundaries of what’s possible in drug development. This partnership highlights the power of our AI platform, GEMS, and our shared commitment to creating innovative and breakthrough medicines for patients with high unmet medical need. Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies | Business Wirehttps://lnkd.in/g6d_gFBA
The Genesis team is excited to be attending #ICML2024 in Vienna this week, July 21-27. We’re proud to be sponsoring ML4LMS as well as the SPIGM Workshop where our Director of Machine Learning, Maruan Al-Shedivat, PhD, will be giving a talk on Generative Modeling in Drug Discovery. If you’re at ICML, we’d love to connect with you - if you would like to chat with a member of our technical team, sign up here: http://bit.ly/4dcTuiw

Join now to see what you are missing

Join now

Genesis Therapeutics | LinkedIn (original) (raw)

Biotechnology Research

Burlingame, California 11,439 followers

Unifying AI and Biotech to accelerate the discovery of new medicines

About us

Locations

Employees at Genesis Therapeutics

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding